

Zai Lab reports positive Phase 1 data for ZL-1503, showing 90% biomarker inhibition through Week 12 and strong safety in healthy volunteers.
You can purchase shares of Zai Lab (NASDAQ:ZLAB) through any online brokerage.
Other companies in Zai Lab’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Zai Lab has a consensus price target of $45.95.
The stock price for Zai Lab (NASDAQ: ZLAB) is $21.03 last updated November 20, 2026 at 4:00 PM EST.
There are no upcoming dividends for Zai Lab.
Zai Lab does not have any upcoming earnings scheduled.
There is no upcoming split for Zai Lab.
Zai Lab is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious...